Peptide antagonists of cellular mitogenesis and motogenesis and their therapeutic use
申请人:Pharmacia & Upjohn S.p.A.
公开号:US06245742B1
公开(公告)日:2001-06-12
The present invention relates to peptides and peptidomimetic compounds and pharmaceutical compositions containing them as useful pharmacological agents in the control or treatment of proliferative diseases such as cancer, against tumor growing and/or tumoral metastasis, and psoriasis and in the control or treatment of inflammatory, allergic, autoimmune, viral, and cardiovascular diseases. These new compounds have the unique property to inhibit the recognition of several phosphotyrosine containing motifs within all the cellular receptors and cytosolic transducers by a wide spectrum of SH2 domains contained in cytosolic transducers and other effector proteins laying along different pathways of the signal transduction process and with a particularly high affinity for the SH2 domain of the adaptor transducer Grb2, a key element along the pathway to mitogenesis and motogenesis, this last activity leading to invasiveness and to metastasis. The invention also relates to methods for production of the compounds and methods of treatment employing the compounds.
本发明涉及肽和类肽类化合物以及含有它们的药物组合物,作为对增殖性疾病(如癌症,对抗肿瘤生长和/或肿瘤转移,以及银屑病)的有用药理剂控制或治疗,以及对炎症,过敏,自身免疫,病毒和心血管疾病的控制或治疗。这些新化合物具有独特的特性,可以抑制所有细胞受体和细胞质传导体中包含的多个含磷酸酪氨酸的结构的识别,通过信号转导过程中不同通路上的多种SH2结构域以及其他效应蛋白质,这些化合物对于适配器传导体Grb2的SH2结构域具有特别高的亲和力,是导致有丝分裂和运动的途径中的关键元素,这种最后的活性导致侵袭性和转移。本发明还涉及制备这些化合物的方法以及使用这些化合物的治疗方法。